Pulse+/ Alzheimer’s Diagnostics: How the Digital Biomarkers Program is Changing the Game

Imagine a world where the earliest signs of Alzheimer’s disease could be detected not just through a brain scan or a clinic visit, but from the rhythm of your daily life—how you walk, the speed of your typing, or the subtle changes in your voice. This isn’t science fiction; it’s the powerful vision behind the Diagnostics Accelerator (DxA) Digital Biomarkers Program.

Launched by the Alzheimer’s Drug Discovery Foundation (ADDF) in partnership with major philanthropists and organizations, this program is on a mission to revolutionize how we diagnose and monitor Alzheimer’s and other dementias. At its heart is a simple, yet profound, idea: to develop affordable, accessible, and non-invasive diagnostic tools that can be used anywhere.

What Are Digital Biomarkers?

Before we dive into the program's work, let's understand the star of the show: digital biomarkers.

Think of a traditional biomarker, like cholesterol levels for heart disease. It's a measurable indicator of a biological process. A digital biomarker is the same concept, but the data is collected continuously and passively through digital devices you might already use. This includes:

• Smartphones and tablets: Measuring things like typing speed, swiping patterns, or how you interact with an app.

• Wearable devices: Tracking physical activity, gait, sleep quality, and heart rate.

• Sensors and software: Analyzing changes in speech, memory, or even eye movements.

Unlike a one-time blood test at a doctor's office, digital biomarkers offer a real-time, continuous stream of data. This "real-world evidence" can capture subtle, day-to-day fluctuations that might be missed in a single clinical setting, providing a much richer picture of a person's health over time.

The Program in Action: A Venture Philanthropy Approach

The DxA Digital Biomarkers Program operates on a "venture philanthropy" model, which means it takes calculated risks on innovative, early-stage ideas that traditional investors might overlook. It funds promising research in both academia and the biotech industry, challenging the research community to think outside the box.

The program's portfolio is diverse, funding projects that range from the development of mobile apps to the use of advanced sensors. For example, the DxA has funded a project with a company to adapt a well-established memory test into a mobile app. This allows a person to take the test from the comfort of their home, enabling regular, frequent testing to track memory changes over time. Another project focuses on using speech analysis and keystroke tracking to detect early cognitive decline.

A key part of the program's work is its commitment to data sharing. By partnering with organizations that create open data repositories, the DxA ensures that the valuable information collected from these projects is shared with the broader research community. This collaborative approach helps accelerate the pace of discovery and development for everyone.

A New Era of Diagnostics

The impact of this program is already being felt. By focusing on digital biomarkers, the DxA is helping to move the field of Alzheimer's diagnostics from expensive, invasive, and episodic tests to tools that are accessible, affordable, and can be used on a daily basis.

This shift has a number of powerful benefits. It can lead to earlier detection, allowing for more timely intervention and personalized treatment plans. It can also make clinical trials more efficient by providing objective, continuous data to measure a treatment's effectiveness.

About DxA

The Diagnostics Accelerator (DxA) is a global research initiative launched in July 2018 with $100 million in funding. The primary goal of the DxA is to accelerate the development of innovative biomarkers. These biomarkers are crucial for the early detection of Alzheimer's disease and related dementias.

The DxA is supported by a diverse group of influential partners, including co-founder of the Alzheimer's Drug Discovery Foundation (ADDF) Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Scott. Other significant contributors include the Dolby family, the Charles and Helen Schwab Foundation, and The Association for Frontotemporal Degeneration. This collective effort brings together leading philanthropists and organizations to drive critical research forward in the fight against neurodegenerative diseases.

Ultimately, the Diagnostics Accelerator Digital Biomarkers Program isn't just funding technology—it's investing in a future where a diagnosis of Alzheimer's isn't a long, uncertain journey, but a clear, data-driven process that empowers patients, doctors, and researchers alike.

Future of Health: An Intro to Digital Health Innovation

Buy Now